SLC7A11 Knockout cell line （Caco-2）

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

SLC7A11 (solute carrier family 7 member 11) encodes the light-chain component of the heteromeric amino acid transporter system Xc−, which exchanges extracellular cystine for intracellular glutamate independently of sodium. By supplying cystine for glutathione synthesis, SLC7A11 supports cellular antioxidant defense and protection from oxidative stress. Its activity also influences extracellular glutamate levels. Increased SLC7A11 expression has been observed in gliomas and has been linked to enhanced glutamate release and neuronal toxicity.

Caco-2 is a human colorectal adenocarcinoma cell line established from a primary colon tumor of a 72-year-old male patient. The cells can form differentiated intestinal epithelial-like monolayers with characteristics including microvilli, tight junctions, dome formation, and transport functionality. Caco-2 cells also produce mucus and can form moderately differentiated adenocarcinoma-like tumors in nude mice. The cell line is widely used as an in vitro model for studying intestinal epithelial differentiation, barrier function, permeability, drug absorption, and colorectal cancer biology.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.